Lin Mao-Yuan, General Manager of Gongwin Biopharm, stated yesterday (15th) that since the launch of their new drug PTS for treating severe tracheal obstruction in central lung cancer in China in August last year, 52 hospitals have already completed the first prescription, with an expected increase to 90 by July. In addition to China, PTS is also applying for approval in Singapore, with plans to further penetrate the ASEAN and Australian markets.
Read more
